- Home
- ZNTL vs IVVD Comparison
ZNTL vs IVVD Comparison
Compare ZNTL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- IVVD
- Stock Information
- Founded
- ZNTL 2014
- IVVD 2020
- Country
- ZNTL United States
- IVVD United States
- Employees
- ZNTL N/A
- IVVD N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- IVVD Health Care
- Exchange
- ZNTL Nasdaq
- IVVD Nasdaq
- Market Cap
- ZNTL 105.8M
- IVVD 96.7M
- IPO Year
- ZNTL 2020
- IVVD 2021
- Fundamental
- Price
- ZNTL $1.34
- IVVD $0.73
- Analyst Decision
- ZNTL Buy
- IVVD Strong Buy
- Analyst Count
- ZNTL 7
- IVVD 3
- Target Price
- ZNTL $8.60
- IVVD $5.85
- AVG Volume (30 Days)
- ZNTL 772.3K
- IVVD 681.0K
- Earning Date
- ZNTL 08-12-2025
- IVVD 08-13-2025
- Dividend Yield
- ZNTL N/A
- IVVD N/A
- EPS Growth
- ZNTL N/A
- IVVD N/A
- EPS
- ZNTL N/A
- IVVD N/A
- Revenue
- ZNTL $26,865,000.00
- IVVD $36,688,000.00
- Revenue This Year
- ZNTL N/A
- IVVD $345.16
- Revenue Next Year
- ZNTL N/A
- IVVD $161.08
- P/E Ratio
- ZNTL N/A
- IVVD N/A
- Revenue Growth
- ZNTL N/A
- IVVD N/A
- 52 Week Low
- ZNTL $1.01
- IVVD $0.35
- 52 Week High
- ZNTL $5.44
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- ZNTL 46.92
- IVVD 46.86
- Support Level
- ZNTL $1.34
- IVVD $0.68
- Resistance Level
- ZNTL $1.48
- IVVD $0.86
- Average True Range (ATR)
- ZNTL 0.08
- IVVD 0.05
- MACD
- ZNTL -0.01
- IVVD -0.00
- Stochastic Oscillator
- ZNTL 21.74
- IVVD 36.09
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.